Exagen (XGN) CEO Aballi covers RSU taxes and buys shares via ESPP

Rhea-AI Filing Summary

Exagen Inc. President and CEO John Aballi reported both a sale and a purchase of company stock. He sold 15,698 shares of common stock at an average price of $3.62 per share, with the sale carried out at the issuer’s direction solely to cover tax withholding on vested restricted stock units, not as a discretionary trade. He also acquired 2,535 shares of common stock at $3.077 per share through the company’s Employee Stock Purchase Plan, a plan-based share purchase. After these transactions, he directly held 689,834 common shares, and an additional 40,401 shares were held indirectly by his spouse.

Insights

Equity compensation and insider-trading analyst

CEO activity reflects routine tax withholding and plan-based share purchases.

The CEO of Exagen Inc., John Aballi, reported selling 15,698 common shares at $3.62 per share. Footnote language states this sale was mandated by the company to cover tax withholding on restricted stock unit vesting, meaning it was not a discretionary open-market decision.

He also acquired 2,535 common shares at $3.077 per share through the Employee Stock Purchase Plan, described as a voluntary plan-based acquisition exempt under Rule 16b-3. These moves are typical of equity compensation programs, and overall reported holdings after the transactions remain sizable.

Subsequent filings may provide additional detail on future equity awards, vesting events, or further ESPP participation, which together shape the longer-term pattern of his ownership stake in the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ABALLI JOHN

(Last) (First) (Middle)

C/O EXAGEN INC.

1261 LIBERTY WAY

(Street)

VISTA CA 92081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXAGEN INC. [ XGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		15,698	D	$3.62	687,299	D
Common Stock(2)	03/03/2026		A	V	2,535(3)	A	$3.077	689,834	D
Common Stock								40,401	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person, at the direction of the Issuer, to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated solely by the Issuer and does not represent a discretionary transaction by the Reporting Person.

2. The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP").

3. Represents shares of common stock purchased through ESPP in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	/s/ Jeffrey G. Black, as attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Exagen (XGN) CEO John Aballi report?

John Aballi reported both a sale and a purchase of Exagen stock. He sold 15,698 shares at $3.62 per share to cover tax withholding on vested restricted stock units and acquired 2,535 shares at $3.077 per share through the Employee Stock Purchase Plan.

Was the Exagen (XGN) CEO’s recent stock sale a discretionary trade?

The reported sale was not discretionary. Footnotes state the 15,698 shares were sold at the issuer’s direction solely to cover tax withholding obligations from restricted stock unit vesting, meaning the transaction was mandated for tax purposes rather than an open-market decision.

How many Exagen (XGN) shares did the CEO acquire through the ESPP?

John Aballi acquired 2,535 shares of Exagen common stock at $3.077 per share through the Employee Stock Purchase Plan. The filing notes this ESPP purchase is voluntarily reported and was exempt under Rule 16b-3(d) and Rule 16b-3(c) governing certain insider transactions.

What are John Aballi’s Exagen (XGN) share holdings after these transactions?

After the reported transactions, John Aballi directly held 689,834 shares of Exagen common stock. The filing also shows an additional 40,401 shares held indirectly by his spouse, reflecting separate indirect ownership alongside his direct holdings reported in the Form 4 filing.

What prices were involved in the Exagen (XGN) CEO’s Form 4 transactions?

The sale of 15,698 Exagen shares was executed at an average price of $3.62 per share. The ESPP acquisition of 2,535 shares occurred at $3.077 per share. These prices apply specifically to the transactions reported for March 3, 2026, in the Form 4.

How does the Exagen (XGN) Form 4 describe the ESPP stock purchase?

The ESPP purchase is described as an acquisition of Exagen common stock under the Employee Stock Purchase Plan. The filing notes the transaction is voluntarily reported, represents a plan-based acquisition, and is exempt under Rule 16b-3(d) and Rule 16b-3(c) governing insider equity compensation transactions.